TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06010940

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement
Description: nasogastric tube and oral care

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: nasogastric tube and oral care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
Study: NCT00056407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
Study: NCT00922155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: guide sheath
Description: The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
Study: NCT00390117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDKI AT7519
Description: AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
Study: NCT04389112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
Study: NCT03289832

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crucera-SGS
Description: Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crucera-SGS
Description: Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meriva 500-SF
Description: Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meriva 500-SF
Description: Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
Study: NCT03483805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protalsafe
Description: mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maize maltodextrin in powder form, to be diluted in water
Study: NCT00413920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
Study: NCT00413920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
Study: NCT00364000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: label sevelamer (RenagelR) 800 mg tablets
Study: NCT00413920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral tablets
Study: NCT02434354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
Study: NCT00919867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD503
Description: SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VYVANSE
Description: VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD503 and VYVANSE
Description: SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Study: NCT02480400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
Study: NCT03136159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver-impregnated antimicrobial dressing
Description: All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
Study: NCT03926806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain yoghurt
Description: cups of 200 g yoghurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B yoghurt
Description: cups of 200 g yoghurt
Study: NCT01810848

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control is puncture of the skin at the site of the knee.
Study: NCT03952117

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
Study: NCT04442256

Intervention type: DRUG
Group type: OTHER
Intervention: Dupilumab
Description: All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
Study: NCT01620151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended neck with standard support or pillow
Description: Patient will undergo thyroid surgery with an extended neck
Study: NCT01079013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan
Description: 12 g/m2 x 3 days
Study: NCT04897919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet
Description: Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
Study: NCT03964974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)
Description: Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Description: The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
Study: NCT01205633

Intervention type: PROCEDURE
Intervention: venous angioplasty
Description: catheter venous angioplasty via femoral vein approach
Study: NCT01742494

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water-jet POEM
Description: Water-jet assisted POEM procedure was performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional POEM
Description: POEM were performed by the use of conventional technique using injection and triangle tip knife.
Study: NCT01439854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Treatment arm, 10 mg per day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are treated with placebo
Study: NCT03049852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-001 single dose
Description: One drop in the study administered one time
Study: NCT04897919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Description: Artemether-Lumefantrine is given as recommended by manufacturer
Study: NCT03049852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop in the study administered three times daily (TID) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-001 Multi-dose
Description: One drop in the study administered three times daily (TID) for 4 weeks
Study: NCT00505037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Description: Oral
Study: NCT03762616

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Micro-ultrasound targeted biopsy
Description: Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI targeted biopsy
Description: Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
Study: NCT04697888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
Study: NCT03761628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pHyph, Gedea pessary
Description: pHyph is a vaginal tablet for the treatment of VVC
Study: NCT04465877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-662
Description: Active drug tablets containing JTT-662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-662
Description: Active drug tablets containing JTT-662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-662
Description: Active drug tablets containing JTT-662

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching in appearance to the active drug tablets
Study: NCT01804712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
Study: NCT02081638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Daily Asprin daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Daily Asprin daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily Atorvastatin Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily Atorvastatin Daily
Study: NCT03350724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: episil wound dressing
Description: Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
Study: NCT04119622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: toripalimab 240 mg d1; q3w, up to two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
Study: NCT03622671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skeletonized LIMA
Description: Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicled LIMA
Description: Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
Study: NCT01845584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Study: NCT03692351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented acetabular cup with screw holes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncemented acetabular cup without screw holes
Study: NCT03350724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PeriAcryl90 wound dressing
Description: PeriAcryl90 is a cyanoacrylate wound dressing.
Study: NCT03792412

Intervention type: OTHER
Group type: OTHER
Intervention: Usability Questionnaire
Description: Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usability Questionnaire
Description: Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
Study: NCT02265445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deescalation therapy
Description: Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
Study: NCT05184465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back.